How to manage regorafenib for a pt on 160-mg dose w/ HFS and painful erythema, swelling (Gr 2)?
How to manage regorafenib for a pt on 160-mg dose w/ HFS and some erythema, skin peeling but no pain (Gr 1)?
A 67-year-old patient with extensive prior treatment for metastatic colorectal cancer (mCRC) is started on regorafenib 160 mg orally daily for 21 days every 28 days. About a week later, the patient develops Grade 2 hand-foot syndrome. What would you do at this time?
Same patient as above, but the patient develops Grade 1 hand-foot syndrome. What would you do at this time?
Belum VR et al. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: A meta-analysis. Invest New Drugs 2013;31(4):1078-86;Abstract
Grothey A et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12. Abstract
Grothey A et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. Proc ASCO 2013;Abstract 3637.
Grothey A et al. Time course of regorafenib-associated adverse events in the phase III CORRECT study. J Clin Oncol 2012;Suppl 34;Abstract 467.
Festino L et al. Critical appraisal of the use of regorafenib in the management of colorectal cancer. Cancer Manag Res 2013;5:49-55. Abstract